'FDA Approves Alzheimer's Drug Leqembi, Paving Way For Broader Medicare Coverage' - CNBC
Portfolio Pulse from Happy Mohamed
The FDA has approved Eisai and Biogen's Alzheimer's treatment Leqembi, which is expected to receive broad coverage through Medicare. The treatment, which costs $26,500 per year, slowed cognitive decline in early Alzheimer's patients by 27% over 18 months during Eisai's clinical trial. However, it carries serious risks of brain swelling and bleeding. Medicare plans to impose conditions on how it will cover Leqembi, requiring patients to find a health-care provider participating in a registry system that collects real-world data on the drug's benefits and risks.
July 06, 2023 | 8:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen, in partnership with Eisai, has received FDA approval for their Alzheimer's treatment Leqembi. This approval and the expected broad Medicare coverage could potentially boost Biogen's revenues.
The FDA approval of Leqembi, a drug developed by Biogen in partnership with Eisai, is a significant milestone for the company. The expected broad Medicare coverage will make the drug accessible to a larger patient population, potentially leading to increased sales and revenues for Biogen. However, the drug's high cost and associated risks may limit its uptake.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100